iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Torrent Pharma logs 20% y-o-y growth in Q1 net profit

24 Jul 2024 , 12:36 PM

On Tuesday (July 23), Torrent Pharmaceuticals Ltd reported a 20.1% YoY rise in net profit of ₹457 Crore for the first quarter ending June 30, 2024. Torrent Pharmaceuticals reported a quarterly net profit of ₹378 Crore in a regulatory filing.

The company’s revenue from operations increased by 10.3% to ₹2,859 Crore from ₹2,591 Crore in the same period last year.

EBITDA climbed 14.3% to ₹904 Crore in the first quarter of this fiscal year, up from ₹791 Crore in the previous year.

The EBITDA margin was 31.6% in the reporting quarter, up from 30.5% in the same period last fiscal year.

The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24, owing to outperformance in focused therapies.

The business also announced that it has signed a non-exclusive licensing agreement with Takeda Pharmaceuticals to commercialise its new potassium-competitive acid blocker (P-CAB) Vonoprazan in India during the June quarter of FY25.

It is used to treat GERD, an acid-related ailment.

Torrent’s chronic business rose by 14%, outpacing the Indian Pharma Market (IPM) growth of 8%. The growth was driven by a strong revival in cardiac divisions and continued traction in anti-diabetes new launches, according to the company’s statement.

Torrent Pharmaceuticals Ltd is an Indian global pharmaceutical firm that is part of the Torrent Group and has its headquarters in Ahmedabad. U. N. Mehta promoted Trinity Laboratories Ltd, which was eventually renamed Torrent Pharmaceuticals Ltd.

At around 12.32 PM, Torrent Pharmaceuticals was trading 3.17% lower at ₹3,039 per piece, against the previous close of ₹3,138.70 on NSE. The counter touched an intraday high and low of ₹3,161.95, and ₹3,002.55, respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Torrent Pharma
  • Torrent Pharma News
  • Torrent Pharma Q1
  • Torrent Pharma Result Update
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.